These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 23123577

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. [Survey of recent clinical trials of the prevention and immunointervention of type 1 diabetes mellitus].
    Boerschmann H, Walter M, Achenbach P, Ziegler AG.
    Dtsch Med Wochenschr; 2010 Feb; 135(8):350-4. PubMed ID: 20166000
    [Abstract] [Full Text] [Related]

  • 47. Immune therapy and β-cell death in type 1 diabetes.
    Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC.
    Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview.
    Rapini N, Schiaffini R, Fierabracci A.
    Int J Mol Sci; 2020 Mar 19; 21(6):. PubMed ID: 32204344
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Young-onset diabetes, nutritional therapy and novel insulin delivery systems: a report from the 21st Hong Kong Diabetes and Cardiovascular Risk Factors - East Meets West Symposium.
    Luk AOY, Kong APS, Basu A.
    Diabet Med; 2020 Aug 19; 37(8):1234-1243. PubMed ID: 32510624
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?
    Pafili K, Papanas N, Maltezos E.
    Expert Opin Investig Drugs; 2014 Sep 19; 23(9):1277-84. PubMed ID: 25079039
    [Abstract] [Full Text] [Related]

  • 57. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
    Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW.
    Diabetes; 2004 Jan 19; 53(1):250-64. PubMed ID: 14693724
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. 2011 Update: antigen-specific therapy in type 1 diabetes.
    Michels AW, von Herrath M.
    Curr Opin Endocrinol Diabetes Obes; 2011 Aug 19; 18(4):235-40. PubMed ID: 21844706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.